(0.23%) 5 143.50 points
(0.24%) 38 535 points
(0.32%) 17 903 points
(-0.79%) $83.19
(1.66%) $1.955
(-0.20%) $2 342.50
(1.04%) $27.54
(0.42%) $926.00
(-0.20%) $0.933
(-0.14%) $11.01
(-0.27%) $0.798
(0.75%) $92.56
Live Chart Being Loaded With Signals
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally...
Stats | |
---|---|
Dagens volum | 185 000 |
Gjennomsnittsvolum | 115 627 |
Markedsverdi | 1.25B |
EPS | HKD0 ( 2023-08-16 ) |
Neste inntjeningsdato | ( HKD0 ) 2024-05-28 |
Last Dividend | HKD0.0450 ( 2023-08-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 4.70 |
ATR14 | HKD0.0130 (0.59%) |
Essex Bio-Technology Ltd Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Essex Bio-Technology Ltd Økonomi
Annual | 2023 |
Omsetning: | HKD1.71B |
Bruttogevinst: | HKD1.54B (90.20 %) |
EPS: | HKD0.480 |
FY | 2023 |
Omsetning: | HKD1.71B |
Bruttogevinst: | HKD1.54B (90.20 %) |
EPS: | HKD0.480 |
FY | 2022 |
Omsetning: | HKD1.32B |
Bruttogevinst: | HKD1.19B (90.26 %) |
EPS: | HKD0.390 |
FY | 2021 |
Omsetning: | HKD1.64B |
Bruttogevinst: | HKD1.40B (85.23 %) |
EPS: | HKD0.600 |
Financial Reports:
No articles found.
Essex Bio-Technology Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0400 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0250 (N/A) |
HKD0.0450 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0100 | 2009-04-30 |
Last Dividend | HKD0.0450 | 2023-08-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD0.602 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.59 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.26 | |
Div. Directional Score | 9.61 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9928.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
2180.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1181.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3888.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1755.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
0798.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
2338.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1313.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0373.HK | Ex Dividend Junior | 2023-05-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.161 | 1.500 | 6.77 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0973 | 1.200 | 6.76 | 8.11 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.145 | -1.000 | 8.55 | -8.55 | [0 - 1] |
currentRatioTTM | 1.536 | 0.800 | 7.32 | 5.86 | [1 - 3] |
quickRatioTTM | 1.425 | 0.800 | 6.32 | 5.06 | [0.8 - 2.5] |
cashRatioTTM | 0.633 | 1.500 | 7.59 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0968 | -1.500 | 8.39 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 21.84 | 1.000 | 3.02 | 3.02 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.588 | 2.00 | 9.80 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.363 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.142 | -1.500 | 9.43 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.902 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.185 | 1.000 | 8.29 | 8.29 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.220 | 1.000 | 4.33 | 4.33 | [0.2 - 2] |
assetTurnoverTTM | 0.604 | 0.800 | 9.31 | 7.45 | [0.5 - 2] |
Total Score | 12.97 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.52 | 1.000 | 9.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.363 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.588 | 2.00 | 9.80 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.145 | 1.500 | 8.55 | -8.55 | [0 - 1] |
pegRatioTTM | 0.0346 | 1.500 | -3.10 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.196 | 1.000 | 7.61 | 0 | [0.1 - 0.5] |
Total Score | 6.26 |
Essex Bio-Technology Ltd
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.